

5. Jiang X-N, Yu B-H, Wang W-G, Zhou X-Y, Li X-Q Anaplastic lymphoma kinase-positive large B-cell lymphoma: Clinico-pathological study of 17 cases with review of literature. PLoS ONE 12(6): e0178416.
6. Paepe P.D, Baens M, Van Krieken H et al. ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood 2003 102:2638-2641.
7. Chikatsu N, Kojima H, Suzukawa K, Shinagawa A, Nagasawa T, Ozawa H, Yamashita Y, Mori N. ALK+, CD30-, CD20- large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC). Mod Pathol 2003 Aug;16(8):828-32.
8. Gascoyne R. D, Lamant L, Martin-Subero J. I et al. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. Blood 2003 Oct 1;102(7):2568-73.
9. Van Roosbroeck K, Cools J, Dierickx D et al. ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions. Haematologica 2010 Mar;95(3):509-13. doi: 10.3324/haematol.2009.014761.
10. Lee HW, Kim K, Kim W, Ko YH. ALK-positive diffuse large B-cell lymphoma: report of three cases. Hematol Oncol. 2008 Jun;26(2):108-13.
11. Reichard KK, McKenna RW, Kroft SH. ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. Mod Pathol. 2007 Mar;20(3): 310-9. Epub 2007.
12. Shi M, Miron PM, Hutchinson L Woda BA, Nath R, Ceny J, Yu H. Anaplastic lymphoma kinase positive large B-cell lymphoma with complex karyotype and novel ALK gene rearrangements Hum Pathol 2011 Oct;42(10):1562-7.
13. Laurent C, Do C, Gascoyne RD, Lamant L, Ysebaert L, Laurent G, Delsol G, Brousset P. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. J clin Oncol 2009;27(25):4211-6.
14. Beltran B, Castillo J, Salas R, Quiñones P, Morales D, Hurtado F, Riva L, Winer E. ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. J Hematol Oncol. 2009 Feb 27;2:11. doi: 10.1186/1756-8722-2-11.
15. Cerchietti L, Damm-Welk C, Vater I, Klapper W, Harder L, Pott C, Yang SN, Reiter A, Siebert R, Melnick A, Woessmann W. Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas. PLoS One 2011; 6: e18436
16. D'Amore ES, Visco C, Menin A, Famengo B, Bonvini P, Lazzari E. et al. STAT3 pathway is activated in ALK-positive large B-cell lymphoma carrying SQSTM1-ALK rearrangement and provides a possible therapeutic target. Am J Surg Pathol. 2013; 37:780.